Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by BearDownAZ


T.RVX

RE:RE:RE:RE:RE:RE:RE:RE:RE:Hung up on adjudication over at Agoracom

RVXeasystreet, I think you need to go back and look and/or listen to the...

January 30, 2019

T.RVX

RE:RE:RE:RE:RE:Hung up on adjudication over at Agoracom

G1945, There are advantages and disadvantages to both scenarios. Surely...

January 30, 2019

T.RVX

RE:RE:RE:Hung up on adjudication over at Agoracom

G1945V, Just a couple comments. My understanding is that once dosing has...

January 30, 2019

T.RVX

RE:RE:Phase IV Trials

The discussion over on Agoracom was mainly focusing on potential of...

January 28, 2019

T.RVX

RE:Bear , in response to Carpe you say...

Fuzzy, Phase 3 BETonMACE is a smallish trial of only ~2400 patients and...

January 27, 2019

T.RVX

RE:RE:8 Data Safety Update... OLD NEWS

G1945V wrote "I believe what was mentioned over at Agoracom is that...

January 27, 2019

T.RVX

RE:rndtbl- poster on IV

Yes, high hsCRP is an important established risk factor for CVD that has been...

January 23, 2019

T.RVX

RE:RE:RE:slide 20#4 Three point MACE event accumulation now stands..

Fuzzy, No disagreement here. To simplify, comes down to 3 scenarios. #1 and ...

January 18, 2019

T.RVX

RE:slide 20#4 Three point MACE event accumulation now stands..

Fuzzy, I don't know why you are so excited about the company reiterating...

January 18, 2019

T.RVX

RE:RE:What they MIGHT disseminate

Good questions Snobei. "By your own assertion earlier, this might not...

January 18, 2019

T.RVX

RE:RE:RE:from Bear = 2019 Potential Events

Sorry. Old link no longer works. Here is a press release for the ODYSSEY CVOT...

January 16, 2019

T.RVX

RE:RE:from Bear = 2019 Potential Events

An example for a drug/trial that you may have heard of before was presented...

January 16, 2019

T.RVX

BETonMACE ClinicalTrials.gov Updated

Well, the last item of the "Waiting Game" list can now be checked...

January 15, 2019

V.BTI.H

RE:RE:Pep Talk - Protein Science Week

"Do you think this will equate to having hard data in hand and released...

January 14, 2019

V.BTI.H

Pep Talk - Protein Science Week

A very impressive collection of speakers and research this week in San Diego...

January 14, 2019

V.BTI.H

RE:RE:Denali/Sirion deal to get AAVs across the BBB

"The initial research was working to find a way to use ultrasound to...

January 11, 2019

T.RVX

RE:RE:RE:RE:RE:RE:RE:Zenith

JK wrote: "ThANKS AGAIN BEAR! WILL THOSE OF US HOLDING ZENITH UNITS HAVE...

January 9, 2019

V.BTI.H

Denali/Sirion deal to get AAVs across the BBB

Denali broadens tech to infiltrate the blood-brain barrier with Sirion deal ...

January 9, 2019

T.RVX

RE:RE:RE:RE:RE:Zenith

I forgot to add that the understanding of how BET inhibition modulates...

January 9, 2019

T.RVX

RE:RE:RE:RE:Zenith

JK, Resverlogix was originally re-organized into two companies back in 2013...

January 9, 2019